Merck’s COVID Manufacturing Deal With US Government Goes Well Beyond J&J Vaccine
‘Wartime’ contract with BARDA will fund up to $268.8m in production site upgrades so Merck can also produce other COVID-19 vaccines and therapeutics as needed.
You may also be interested in...
Agency biologics investigator questioned site classification downgrades and belated response to Merck & Co. plant informant’s concerns.
FDA policy experts Jesse Goodman, Mark McClellan, Peter Lurie, David Bowen, Patti Zettler, and Aaron Kesselheim suggest ideas and points to consider in using the COVID-19 experience to assess whether standards for EUAs should be adjusted.
Biden Administration seeks to put its stamp on a new phase of the US government’s collaboration with the pharma industry against COVID-19.